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SUMMARY
Cells expressing oncogenic c-Myc are sensitized to TNF superfamily proteins. c-Myc also is an
important factor in determining whether a cell is sensitive to TRAIL-induced apoptosis, and it is
well established that the mitochondrial pathway is essential for apoptosis induced by c-Myc. We
investigated whether c-Myc action on the mitochondria is required for TRAIL sensitivity and found
that Myc sensitized cells with defective intrinsic signaling to TRAIL. TRAIL induced expression of
antiapoptotic Mcl-1 and cIAP2 through activation of NF-kB. Both Myc and the multikinase inhibitor
sorafenib block NF-kB. Combining sorafenib with TRAIL in vivo showed dramatic efficacy in
TRAIL-resistant tumor xenografts. We propose the combination of TRAIL with sorafenib holds prom-
ise for further development.INTRODUCTION
TNF-a-related apoptosis-inducing ligand (TRAIL, also
known as Apo2L) is a member of the TNF family of death
receptor ligands and has significant potential for use in66 Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc.cancer therapy because of its potent ability to selectively
kill cancer cells while leaving normal cells unharmed (Kel-
ley and Ashkenazi, 2004). TRAIL-based therapies are now
in Phase I and II clinical trials (www.clinicaltrials.gov).
TRAIL activates the extrinsic pathway of apoptosis bySIGNIFICANCE
Activation of TRAIL death receptor signaling provides an exciting approach for cancer therapy because of its
potency and lack of significant toxicity. Unfortunately, certain defects in the apoptosis signaling pathway can
confer resistance to TRAIL. One approach to optimize TRAIL therapy is to pharmacologically enhance sensitivity
to TRAIL. We found that combining TRAIL with either the multikinase inhibitor sorafenib or with oncogenic c-Myc
sensitizes bax/ cells to TRAIL through a mechanism involving downregulation of TRAIL-induced Mcl-1 and
cIAP2 expression. TRAIL activates NF-kB, which regulates Mcl-1 and cIAP2 expression, and sorafenib decreases
NF-kB binding at these promoters. We propose use of sorafenib as a potent sensitizer of cancer cells, especially
those harboring apoptotic defects to TRAIL-mediated death.
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Repressing TRAIL-Induced Mcl-1 and cIAP2binding one of two transmembrane cell surface receptors,
Death Receptor 4 (DR4) or Death Receptor 5 (DR5) (Jin
and El-Deiry, 2005). After binding TRAIL, these receptors
form homotrimers that signal through the adaptor protein
FADD. FADD recruits caspases 8/10, which then self-ac-
tivate and initiate downstream caspase cleavage events.
An unanswered question that has gained evenmore sig-
nificance now that TRAIL therapy has entered the clinic is
what biomarkers are available to identify patients likely to
respond to TRAIL therapy? We showed c-Myc to be a key
mediator of cancer cell sensitivity to apoptosis induced by
TRAIL (Ricci et al., 2004). We found that levels of endoge-
nous c-Myc significantly correlated with TRAIL sensitivity
in a panel of cancer cell lines.We identified c-FLIP as a tar-
get of c-Myc-mediated transcriptional repression. c-FLIP,
which is highly homologous to caspase 8 but is catalyti-
cally inactive, can bind caspase 8 and FADD and block
caspase 8 activation (Irmler et al., 1997; Shu et al., 1997).
Downregulation of FLIP expression results in sensitization
to TRAIL-induced apoptosis. If Myc expression results
in decreased FLIP, this can increase a cell’s ability to un-
dergo apoptosis following TRAIL activation of the extrinsic
pathway. These results suggested that cells expressing
oncogenic levels of Myc and having defects in their intrin-
sic pathway of apoptosis (e.g., Bax deficiency) might still
be sensitive to TRAIL.
To test whether c-Myc can bypass the mitochondria
and sensitize cells to TRAIL, we used bax/ HCT116
human colon carcinoma cells that are resistant to TRAIL
(Burns and El-Deiry, 2001). c-Myc overexpression results
not only in cell proliferation but also in apoptotic cell death,
and it appears critical that the intrinsic pathway of apopto-
sis is inactivated for c-Myc to promote tumorigenesis
(Askew et al., 1991; Evan et al., 1992). Intrinsic pathway
activation is predicated on destabilization of the outer mi-
tochondrial membrane following oligomerization of proa-
poptotic members of the Bcl-2 superfamily, such as Bax
and Bak. This destabilization results in the release of cyto-
chrome c and other factors that initiate caspase-mediated
apoptotic cell death. The exact mechanisms that explain
c-Myc-induced alterations of the proteins involved in
maintaining mitochondrial membrane integrity may not be
consistent across cell and tissue types, but it is clear that
c-Myc exerts a powerful effect on the mitochondria (Juin
et al., 1999, 2002; Mitchell et al., 2000; Soucie et al., 2001).
We found that increasing c-Myc expression in bax/
cells sensitizes them to TRAIL. We also found that TRAIL
dramatically induces expression of two potent antiapop-
totic molecules, cellular inhibitor of apoptosis protein 2
(cIAP2) and the Bcl2 family member, Mcl-1. Myc expres-
sion represses TRAIL-induction of both Mcl-1 and cIAP2.
In an attempt tomimicMyc action in bax/ cells, we com-
bined the multikinase inhibitor sorafenib with TRAIL. Sor-
afenib targets both the RAF/MEK/ERK signaling pathway
to inhibit cell proliferation and the VEGFR-2/PDGFR-b
signaling cascade to inhibit tumor angiogenesis (Wilhelm
et al., 2004). Sorafenib was recently FDA approved for
treatment of renal cancer and is currently undergoing in-
vestigation in over 30 clinical trials for use against a widerange of human cancers, including melanoma, prostate,
ovarian, pancreatic, lung cancer, and others (www.
clinicaltrials.gov). We found sorafenib sensitizes bax/
cells to TRAIL through a mechanism involving downregu-
lating Mcl-1 and cIAP2 expression. This mechanism in-
volves repression of TRAIL-induced NF-kB transcriptional
activation of both themcl-1 and ciap2 promoters. We pro-
pose that combining sorafenib with TRAIL can sensitize
cancer cells harboring defects in their intrinsic apoptotic
signaling pathway by diminishing TRAIL-induction of anti-
apoptotic proteins.
RESULTS
c-Myc Sensitizes HCT116 bax/ Cells
to TRAIL-Mediated Cell Death
To investigate the importance of the intrinsic pathway for
mediating c-Myc-induced sensitization to TRAIL, we ex-
amined the effect of c-Myc expression in Bax-deficient
HCT116 cells. Parental HCT116 cells are heterozygous
forbax and are referred to herein asHCT116bax+/ (Zhang
et al., 2000). HCT116 bax+/ cells are very sensitive to
TRAIL-induced cell death, but thedeletion of the remaining
bax allele renders these cells TRAIL-resistant (Burns and
El-Deiry, 2001). Adding TRAIL to bax/ cells expressing
c-Myc for 6 hr resulted in modest cell death (8%) that in-
creased to 27% after 24 hr (Figure 1A). A dose-response
analysis showed increasing c-Myc expression sensitized
bax/ cells to TRAIL in a direct, linear manner (Figure 1B).
c-Myc-Mediated Sensitization to TRAIL in bax/
Cells Requires Caspase-9 Activation
We analyzed loss of mitochondrial membrane potential
after TRAIL treatment to investigate whether c-Myc acts
upon the intrinsic apoptotic pathway in bax/ cells.
c-Myc altered membrane potential in bax/ cells and this
effect increased 2-fold after TRAIL treatment (Figure 1C).
TRAIL induced cleavage of procaspase 3 in HCT116
bax/ cells irrespective of c-Myc-expression, but TRAIL
cleaved caspase 9 only in cells expressing c-Myc or Bax
(Figure 1D). We tested whether caspase 9 is required for
c-Myc sensitization to TRAIL by adding a specific inhibitor
of activated caspase 9 (Z-LEHD-FMK). The caspase 9 in-
hibitor completely blocked c-Myc-mediated sensitization
of the bax/ cells to TRAIL (Figure 1E).
TRAIL Resistance in bax/ Cells Involves
TRAIL-Induced CIAP2 and Mcl-1 Expression
Because Bax deficiency does not block TRAIL-induced
Bid cleavage (Figure 2A) (Ravi and Bedi, 2002), we rea-
soned that c-Myc might alter levels of other Bcl-2 family
members. Unexpectedly, we observed that TRAIL in-
duced a profound increase in Mcl-1 protein expression
in the bax/ cells (Figure 2A). Human Mcl-1 is an antia-
poptotic member of the Bcl-2 protein family with similar
BH-multidomain structures as Bcl-2 and Bcl-xL (Reed
et al., 2004). Increased Mcl-1 expression likely confers
additional protection against tBid in TRAIL-treated Bax-
deficient cells. Examination of Bcl-2, Bcl-xL, and BidCancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc. 67
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Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 1. HCT116 bax/ Cells Are Sensitized to TRAIL-Induced Apoptosis by c-Myc
(A) HCT116 bax/ cells were infected with adenoviruses for 24 hr, then treated with TRAIL (50 ng/ml) for 6 hr or 24 hr. Percentages of cells with
sub-G1 DNA content are shown.
(B) bax/ cells were infected with adenoviruses for 24 hr, then treated with TRAIL (125 ng/ml) for 18 hr.
(C) Cells infectedwith non-GFP-expressing adenoviruses for 24 hr were treatedwith TRAIL (50 ng/ml) for the times indicated. Cells were collected and
loss of mitochondria transmembrane potential was measured.
(D) Immunoblots using lysates from HCT116 bax/ cells infected with adenovirus for 24 hr and treated with TRAIL for 6 hr.
(E) HCT116 bax wt cells and HCT116 bax/ cells infected with adenovirus were treated with TRAIL, with or without an inhibitor to caspase 8 (C8I) or
caspase 9 (C9I), for 24 hr.levels in bax/ cells did not show any meaningful
changes in protein levels with Myc expression. Puma ex-
pressionwas diminished in TRAIL-treatedMyc expressing
cells, but Myc alone had no effect. Bim increased with
TRAIL, and Myc expression reduced this induction. Given
that all Bim isoforms are proapoptotic (O’Connor et al.,
1998), these changes in Bim expression do not appear
to impact the mechanism of Myc-mediated sensitization
to TRAIL. TRAIL exposure also resulted in the loss of68 Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc.Bak expression in all treated cells. This observation is
potentially in conflict with evidence showing that either
Bax or Bak are required for apoptosis (Wei et al., 2001).
It is possible that the initial presence of Bak permits the
permeabilization of the outer mitochondrial membrane
and tBid mediates cytochrome c release. A study from
the Korsmeyer Laboratory described a BH3-independent
function of tBid that supports this scenario (Scorrano
et al., 2002). They found that tBid acts to mobilize
Cancer Cell
Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 2. c-Myc Represses TRAIL-Induced cIAP2 and Mcl-1 Expression in bax/ Cells
(A) bax/ cells were infected with the indicated adenoviruses (L = Ad-LacZ; M = Ad-Myc) for 24 hr then treated with TRAIL for 24 hr. HCT116 bax+/
cells were treated with TRAIL for 6 hr and were not infected with adenoviruses.
(B) Cells infected with adenoviruses (24 hr) were treated with TRAIL for the times shown. Total RNA was isolated and northern blot analysis was
performed.
(C) Immunoblots are shown for cells infected with adenoviruses for 24 hr and collected after TRAIL exposure for the times shown.
(D) Cells were infected with Ad-Myc as shown in Figure 1B for 24 hr then treated with TRAIL for 4 hr.cyctochrome c from isolatedmitochondrial cristae into the
intermembrane space and this property of tBid is indepen-
dent of its BH3 domain. A small fraction of cytochrome c is
present in the intermembrane space of mitochondria
(15%) that is quickly released after tBid activation. The
remainder of cytochrome c sequestered in cristae
(85%) is subsequently mobilized to the intermembrane
space by changes in mitochondrial structure initiated by
tBid. It follows that in cells having elevated Mcl-1 expres-
sion, tBid is bound by Mcl-1 (Clohessy et al., 2006) and all
of its proapoptotic activities are inhibited.
We continued our examination of factors that act down-
stream of Bid and are involved in blocking activated cas-
pase 9. Inhibitor of Apoptosis proteins (IAPs) can block
executioner caspases. Specifically, XIAP is a potent inhib-
itor of caspase 9, while cIAP1, cIAP2, and XIAP can inhibit
caspases 3 and 7 (Roy et al., 1997; Shiozaki et al., 2003).
When the mitochondrial membrane is disrupted during
apoptosis, Smac/DIABLO and Omi/Htr2A are released
and these proteins act to inhibit IAPs. c-Myc does not alterexpression of the XIAP, cIAP1, or their controllers in
bax/ cells, but in a manner similar to Mcl-1, we found
that TRAIL induced a profound increase in cIAP2 protein
(Figure 2A).
Oncogenic levels of c-Myc can stabilize p53 protein
levels, and c-Myc expression resulted in the stabilization
of p53 in the bax/ cells (Figure 2A). To test the impor-
tance of p53 in mediating c-Myc sensitization to TRAIL,
we performed p53 siRNA knockdown experiments. We
found that significant reduction in p53 levels did not
change the ability of c-Myc to sensitize bax/ cells to
TRAIL-induced death (see Figure S1 in the Supplemental
Data available with this article online).
c-Myc Represses TRAIL-Induced Mcl-1
and cIAP2 Expression
Myc expression in bax/ cells showed reduced Mcl-1
and cIAP2 proteins andmRNAs following TRAIL treatment
(Figures 2A and 2B). Time-course analysis revealed that
TRAIL rapidly inducedMcl-1 and cIAP2mRNAand proteinCancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc. 69
Cancer Cell
Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 3. TRAIL Signaling Increases cIAP2 and Mcl-1 Expression when Caspase Signaling Is Blocked
(A) HCT116 bax+/ cells stably expressing Bcl-xL or firefly luciferase were generated by retroviral insertions. (Left) Cells were treated with TRAIL for
4 hr. (Center) Cells treated with TRAIL for the times indicated were collected and immunoblot analysis performed. (Right) HCT116-Bcl-xL cells were
infected with the indicated adenoviruses for 24 hr, and then treated with TRAIL for 4 hr. Immunoblots are shown.
(B) HCT116 bax+/ cells were treated with caspase 8 (C8I) or caspase 9 (C9I) inhibitors for 30 min prior to TRAIL exposure. Cells were collected 6 hr
later.
(C and D) Cells were treated with TRAIL for 15 min, collected and DISC immunoprecipitation was performed. In (D), the asterisk indicates the 43 kDa
cleaved form of c-Flip.expression, and this induction was substantially reduced
by c-Myc (Figures 2B and 2C). In contrast to bax/ cells,
the bax+/ cells showed only a slight induction of Mcl-1
protein that quickly disappeared following TRAIL treat-
ment and no induction of cIAP2 (Figure 2C). Examination
of c-Myc expressing cells following TRAIL treatment
showed a clear dose-dependent relationship between
c-Myc and the reduction in Mcl-1 and cIAP2 (Figure 2D).
TRAIL Induces Mcl-1 and cIAP2 in Bax-Expressing
Cells When Apoptosis Is Blocked
To help determine the rolemitochondrial release of factors
plays in TRAIL-induced gene expression, we established
HCT116 bax+/ cells stably expressing Bcl-xL. Cells ex-
pressing Bcl-xL were resistant to TRAIL-induced death
(Figure 3A). TRAIL induced Mcl-1 and cIAP2 in Bcl-xL-ex-
pressing cells, and c-Myc repressed their induction (Fig-
ure 3A). Therefore, when the intrinsic pathway is blocked
by Bcl-xL overexpression or Bax-deficiency, TRAIL medi-
ates induction of the antiapoptotic factors Mcl-1 and
cIAP2.70 Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc.To test whether caspase 9 activation contributes to
TRAIL induction of Mcl-1 and cIAP2, we examined lysates
of bax+/ cells treated with TRAIL plus caspase inhibitors.
Caspase 8 and 9 inhibitors block TRAIL-mediated death of
the bax+/ cells (Figure 1E) and permit the expression of
Mcl-1 and cIAP2 (Figure 3B). HCT116 bax+/ cells are
classified as type II cells, and as such, caspase 8 activity
is not principally responsible for activating executioner
caspases in these cells (Kim et al., 2004; Ozoren and
El-Deiry, 2002). Indeed, inhibition of caspase 9 resulted
in almost complete ablation of TRAIL-induced caspase 8
activity (data not shown), which might result from the inhi-
bition of feedback activation of caspase 8 by executioner
caspases such as caspase 6 (Cowling and Downward,
2002). Therefore, we postulated that if c-Myc alters Death
Inducing Signaling Complex (DISC) formation in bax+/ or
bax/ cells, this is not the principal mechanism for
c-Myc-mediated repression of TRAIL-induced gene ex-
pression. We tested whether c-Myc expression altered
DISC formation by performing DISC immunoprecipita-
tions and found that there were only modestly smaller
amounts of FLIP, DR4, DR5, and caspase 8 at the TRAIL
Cancer Cell
Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 4. NF-kB Mediates TRAIL Activation of Mcl-1 and cIAP2 Transcription
(A) bax/ cells transfected with luciferase reporter plasmids responsive to CREB, NF-kB, or a control were treated with TRAIL for 24 hr. Forskolin was
used as a positive control for CREB activation. Significance of difference for the NF-kB reporter was calculated by Student’s t test analysis. Results
are shown as the mean (bar) ± SD.
(B) bax/ cells treated with 150 ng TRAIL for 2 hr were collected and cytosolic and nuclear extracts prepared. Equal protein amounts of each were
loaded along with whole cell extracts (wce).
(C) bax/ cells were infected with adenovirus expressing IkB-SR or LacZ for 24 hr. Cells were treated with TRAIL (150 ng/ml) for 2 hr, collected, and
cytosolic and nuclear extracts were prepared.
(D) bax/ cells were infected with adenovirus expressing IkB-SR or LacZ for 24 hr. Cells were treated with TRAIL for 6 hr and total lysates prepared.
(E) bax/ cells treated with TNF (10 ng/ml) or TRAIL (50 ng/ml) for 4 hr were subject to chromatin immunoprecipitation analysis using a RelA/p65
antibody or IgG isotype control.
(F) bax/ cells were infected with Ad-Myc for 24 hr then treated with TRAIL for 1.5 hr. ChIP analysis was performed. The two sequences for Mcl-1
refer to upstream (50) and downstream (30) of the Mcl-1 transcriptional start site. CAD is a known Myc target gene.DISC in c-Myc-expressing cells (Figures 3C andD). Dimin-
ished FLIP levels also had no effect on TRAIL induced
Mcl-1 and cIAP2 expression (Figure S4).
Transcriptional Control of Mcl-1 and cIAP2 by TRAIL
ciap2 is awell-characterized transcriptional targetofNF-kB,
potently induced by TNF-a (Wang et al., 1998). Transcrip-
tional control of mcl-1 is less understood, but putative
binding sites for NF-kB were identified in its promoter
region (Moshynska et al., 2004) and both mcl-1 and
ciap2 were found to be c-AMP response element-binding
protein (CREB) targets (Nishihara et al., 2004; Wang et al.,
1999). Multiple kinase signaling pathways, including Raf/
MEK/ERK, phosphorylate and activate CREB. TRAIL has
been shown to activate both NF-kB and the Raf/MEK/
ERK kinase pathway (Harper et al., 2001; Hu et al., 1999;
Morel et al., 2005; Tran et al., 2001; Zhang et al., 2003).
We observed TRAIL rapidly induces ERK phosphorylation
and IkBa degradation, an activating step for NF-kB(Figure 2C). To directly examine whether TRAIL activated
NF-kB or CREB signaling in bax/ cells, we used lucifer-
ase reporter plasmids containing binding sites for CREB
or NF-kB (Figure 4A). These data showed that TRAIL in-
duced NF-kB transactivation but had no effect on CREB.
We further examined the role of NF-kB in mediating
TRAIL action. We observed TRAIL induced a rapid de-
crease in IkBa protein expression after 30 min, and IkBa
levels returned to normal after 2 hr (Figure 2C). Given that
IkBa and ciap2 are known NF-kB target genes, these data
suggest that NF-kB is activated by TRAIL in bax/ cells,
and NF-kB may also regulate mcl-1 (Ito et al., 1994;
Wang et al., 1998). To test this, we examined nuclear ex-
tracts from TRAIL-treated cells and observed the translo-
cation of the RelA/p65 subunit of NF-kB into the nucleus
(Figure 4B). We expressed a nondegradable mutant of
IkBa (IkB-Super Repressor) to test whether NF-kB is re-
quired for TRAIL induction of Mcl-1 and cIAP2. IkB-SR
blocked TRAIL-activation of NF-kB in bax/ cellsCancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc. 71
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Repressing TRAIL-Induced Mcl-1 and cIAP2(Figure 4C) and TRAIL-mediated induction of Mcl-1 and
cIAP2 (Figure 4D). NF-kB inhibition did not alter the cleav-
age of caspase 8 or Bid, but it did result in increased
TRAIL-induced death, visualized by an increase in PARP
cleavage. The cleavage patterns of caspase 8 and Bid in
the presence of IkB-SR are consistent with the interpreta-
tion that the effects of TRAIL occur downstream of and
in spite of Bid processing. We further examined whether
NF-kB can directly activate mcl-1 transcription. ciap2 is
a well-characterized NF-kB target gene that can be acti-
vated by TNF (Wang et al., 1998). We performed chroma-
tin immunoprecipitation using antibody to the RelA/p65
subunit of NF-kB following TRAIL and TNF treatment
and found that it binds to both the mcl-1 and ciap2 pro-
moters (Figure 4E).
The northern blot data suggest thatMyc regulatesmcl-1
and ciap2 at the level of transcription (Figure 2B). To con-
firm this, we performed ChIP using Ad-Myc infected
bax/ cells and found Myc bound to both the mcl-1
and ciap2 promoters (Figure 4F). Addition of TRAIL did
not significantly alter Myc binding. This suggests that
TRAIL does not alter Myc regulation of mcl-1 and ciap2,
but that Myc may alter TRAIL action on NF-kB. There
are several reports showing Myc suppression of NF-kB
function, but a clear consensus on the mechanism is lack-
ing (Keller et al., 2005; Klefstrom et al., 1997; Sitcheran
et al., 2005; Tanaka et al., 2002; You et al., 2002). For ex-
ample, one report shows that B cells derived from Em-Myc
mice have reduced NF-kB expression and DNA-binding
activity (Keller et al., 2005). We examined whether Myc
regulates NF-kB expression in bax/ cells, and found
that Myc does not significantly diminish NF-kB subunit
protein levels or their translocation to the nucleus follow-
ing TRAIL treatment (Figure S2A).
The Kinase Inhibitor Sorafenib Sensitizes
bax/ Cells to TRAIL
In parallel with our experiments examining transcriptional
control of mcl-1 and ciap2 following TRAIL treatment, we
explored the importance of Raf/MEK/ERK signaling
downstream of TRAIL. We tested whether Raf/MEK/ERK
signaling altered mcl-1 and ciap2 transcription in bax/
cells by treating them with phorbol 12-myristate 13-ace-
tate (PMA), a known inducer of Raf/MEK/ERK signaling
(Figure 5A) (Ueda et al., 1996). PMA rapidly and potently
induced Mcl-1 and cIAP2 in bax+/ and bax/ cells (Fig-ures 5B and 5C). Interestingly, PMA activated NF-kB
signaling but not CREB using the luciferase reporter
(Figure 4A), suggesting that p-ERK signaling does not ac-
tivate cREB in bax/ cells. We tested whether Raf signal-
ing was directly involved in mediating TRAIL activation of
Mcl-1 and cIAP2 by blocking the kinase pathway using
sorafenib, a potent inhibitor of Raf1 (Wilhelm et al.,
2004). bax/ cells treated with the combination of TRAIL
plus increasing concentrations of sorafenib showed a
dose-dependent sensitization to TRAIL by sorafenib
(Figure 5D). bax+/ cells were also sensitized to TRAIL
by sorafenib (Figure 5E). Doses of sorafenib that sensi-
tized bax/ cells to TRAIL also resulted in reduced levels
of TRAIL-induced Mcl-1 and cIAP2 (Figure 5F). We made
similar observations of the sensitizing effects of sorafenib
on TRAIL-induced apoptosis using TRAIL-resistant Calu6,
HT29, and RKO human tumor cells (Figure 8A). Confirming
the functionality of the Raf inhibitor, we observed that
sorafenib reduced constitutively high levels of phosphory-
lated MEK and ERK1/2 in the bax/ cells (Figure 5F).
TRAIL alone does change the status of phosphorylated
CREB (p-CREB), which is in agreement with results using
the luciferase reporters (Figure 4A), but its combination
with sorafenib results in its decrease (Figure 5I). Therefore,
the reduction of p-CREB may contribute to the regulation
of Mcl-1 expression by the combination of TRAIL and sor-
afenib. Because GSK3b can regulate both Myc and Mcl-1
protein levels (Gregory et al., 2003;Maurer et al., 2006), we
examined whether sorafenib might act on both Myc and
Mcl-1 through this pathway. We did not see any observ-
able effects on phosphorylation of GSK3b by TRAIL, sor-
afenib, or their combination (data not shown). Examination
of whether Myc has a role in mediating sensitization by
sorafenib showed a dramatic loss of endogenous Myc fol-
lowing sorafenib treatment (Figure 5I). This suggests that
the signaling pathways leading to loss of Mcl-1 and
cIAP2 expression activated by sorafenib do not involve
upregulation of endogenous c-Myc.
Because NF-kB mediates mcl-1 and ciap2 transcrip-
tional activation and inhibition of Raf/MEK/ERK can block
TRAIL action, we examined whether sorafenib can disrupt
TRAIL signaling through NF-kB. We found that sorafenib
reduces the amount of TRAIL activated NF-kB bound to
the mcl-1 and ciap2 promoters using ChIP (Figure 5H).
Sorafenib also significantly decreased TRAIL-induced
mRNA levels, as would be expected with a loss ofFigure 5. TRAIL signals through the Raf/MEK/ERK pathway to induce cIAP2 and Mcl-1 expression
(A) bax/ cells were treated with 50 ng/ml PMA for 6 hr and immunoblot analysis was performed.
(B) HCT116 bax+/ cells were treated with TRAIL (10 ng/ml) and PMA (50 ng/ml) for 6 hr.
(C) bax/ cells were treated with 35, 63, or 125 ng/ml TRAIL, or 12.5, 25, or 50 ng/ml PMA for 6 hr.
(D) Sorafenib was added to bax/ cells at the concentration shown. TRAIL was added 1 hr later. Fifteen hours later, cells were collected and stained
with propidium iodide. Results are shown as the mean ± SD.
(E) bax+/ cells were treated with sorafenib for 1 hr prior to addition of TRAIL (10 ng/ml) for 6 hr. Results are shown as the mean (bar) ± SD.
(F) Cells treated as in D. were collected, lysed and immunoblotting was performed.
(G)bax/cellswere treatedwithTRAIL (50ng/ml) or sorafenib (16mM) for 4hr,RNAcollectedandquantitativeRT-PCRanalysisperformed.mRNA levels
normalized to GAPDH are shown. Results are shown as the mean (bar) ± SD. Significance of difference was calculated using Student’s t test analysis.
(H) Chromatin immunoprecipitation analysis using bax/ cells treated for 4 hr was performed for the treatments indicated.
(I) bax/ cells were treated with TRAIL or sorafenib for the times indicated.Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc. 73
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Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 6. Mcl-1 Is a Critical Mediator of TRAIL Resistance
(A) HCT116 bax+/ cells were transiently transfected with expression plasmids for cIAP2, Mcl-1, both or the empty vector (C, M, B, or V) for 24 hr. Cells
then were treated with TRAIL for 6 hr. An expression plasmid for GFP-Spectrin was also added at 10% of the total DNA. The percentages of apoptotic
cells expressing GFP are shown (p < 7.7 3 105). Immunoblots are shown in on the right.
(B) bax/ cells transfected with siRNA were treated as shown for 5 hr. Cells were collected and analyzed for DNA content or protein expression
(p < 0.0097).
(C) bax/ cells were transfected as in (A) for 6 hr then infected with the indicated adenoviruses (LacZ or Myc) for 15 hr. After this, cells were treated
with TRAIL for 6 hr, collected and stained with propidium iodide (left panel), or extracts were analyzed by immunoblotting (right).
(D) bax/ cells were transfected, and 24 hr later treated with sorafenib (16 mM) for 1 hr followed by TRAIL treatment for 6 hr. Cells were collected and
stained (left panel) or extracts were analyzed by immunoblotting (right). The data represents the average of 6 measurements collected from three
separate experiments and Mcl-1 overexpression is significantly different from control in TRAIL + sorafenib treated cells (p < 0.0044). Sub G1 results
are shown as the mean (bar) ± SD in (A)–(D). Significance of difference was calculated by Student’s t test analysis.promoter-bound NF-kB (Figure 5G). Use of reporter plas-
mids containing the mcl-1 or ciap2 promoters showed
similar decrease of TRAIL-induced activity by sorafenib
(Figure S6). TRAIL-induced luciferase activity was lost
when NF-kB binding sites were mutated in either mcl-1
or ciap2 promoters. The importance of the NF-kB binding
site in themcl-1 promoter was confirmed by ChIP analysis
of the five potential relevant NF-kB sites in the Mcl-1gene
(Figure S7). This region of the mcl-1 promoter showed
increased acetylation of histone H3 following TRAIL treat-
ment, and both anti-p65/RelA and anti-Acetyl-H3 anti-
bodies showed reduced binding with sorafenib treatment.
Examination of the effect of sorafenib on both TRAIL-in-
duced degradation of IkBa and NF-kB translocation into
the nucleus showed no significant changes (Figure S3).
These data show sorafenib sensitizes bax/ cells to
TRAIL, in part, by disrupting NF-kB transcriptional activa-
tion of mcl-1 and ciap2.
Mcl-1 Is a Critical Mediator of TRAIL Resistance
in bax/ Cells
To assess the importance of Mcl-1 and cIAP2 in mediat-
ing resistance to TRAIL, we expressed these proteins in
bax+/ cells and tested for changes in TRAIL sensitivity.
Mcl-1 provided significant protection from TRAIL, but
cIAP2 expression did not (Figure 6A). We used siRNA to
assess the importance of Mcl-1 and cIAP2 in mediating
TRAIL resistance and observed Mcl-1 knockdown in-
creased TRAIL-induced apoptosis by close to 2-fold74 Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc.(Figure 6B), whereas knockdown of cIAP2 in bax/ cells
did not enhance TRAIL-mediated death (Figure 6B). Be-
cause control siRNA showed some sensitization to TRAIL,
we included siRNA to Bak as an additional negative con-
trol. These results suggest that Mcl-1 may bemore impor-
tant than cIAP2 in mediating TRAIL-induced resistance to
the TRAIL death signal.
Mcl-1 Expression Protects Cells from c-Myc
and Sorafenib Sensitization to TRAIL
We tested whether Mcl-1 and cIAP2 were critical media-
tors of TRAIL sensitization by Myc or sorafenib. Transient
transfection of bax/ cells withMcl-1 and cIAP2, followed
by infection using LacZ- or c-Myc-expressing adenovirus
produced a large amount of background apoptosis that
was reduced by Mcl-1 (Figure 6C). Addition of TRAIL to
these cells recapitulated the Myc sensitization, but the
dramatic differences seen compared to the controls was
masked by the high level of background death. Neverthe-
less, Mcl-1 clearly exerted protection against the various
apoptotic signals: TRAIL, c-Myc, and introduction of ex-
ogenous DNA. We used the same approach to examine
the significance of Mcl-1 and cIAP2 in protecting cells
from sensitization to TRAIL by sorafenib. Again, Mcl-1
protected bax/ cells from sorafenib, and DNA trans-
fection mediated death while also protecting the cells
from this combination plus TRAIL (Figure 6D). These ex-
periments indicate that cIAP2may not be critical for TRAIL
resistance in bax/ cells and that Mcl-1 likely plays a
Cancer Cell
Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 7. TRAIL Combined with Sorafe-
nib Prevents Growth of bax/ Tumor
Xenografts
Mice bearing luciferase-expressing HCT116
bax/ tumor xenografts received TRAIL plus
sorafenib. TRAIL was administered once on
days 1 and 3. Sorafenib was administered
once on each day for 5 days (days 0–4). Lucifer-
ase activity was measured on days 0, 2, and 4.
(A) Control (n = 7).
(B)TRAILplussorafenib, i.p.administration (n=5).
(C) TRAIL plus sorafenib, oral administration
(n = 5).
(D) Summary of data from experiments shown
in (A)–(C). Mean value of each group was
marked as a short horizontal solid line. Signifi-
cance of difference was calculated by Stu-
dent’s t test analysis.
(E) Model of TRAIL action. TRAIL can activate
caspase 9, NF-kB, and Raf/ERK signaling. If
caspase 9 activation is blocked (i.e., by Bax
deficiency), NF-kB acts directly to increase
Mcl-1 and cIAP2 transcription, which can be
blocked byMyc or sorafenib. Sorafenib inhibits
Raf/ERK, affecting multiple targets, including
NF-kB. Decreased levels of TRAIL-induced
antiapoptotic proteins, including Mcl-1 and
cIAP2, override the defect in intrinsic apoptotic
signaling resulting in cell death.major role in offering protection from TRAIL-induced
death.
Sorafenib Combined with TRAIL Caused Regression
of TRAIL-Resistant Tumors In Vivo
To assess the in vivo efficacy of combining TRAIL and sor-
afenib, we tested these compounds using mouse tumor
xenograft models monitored with in vivo bioluminescence
technology. Mice bearing luciferase-expressing bax/
tumors were treated with daily doses of sorafenib for
5 days, and two doses of TRAIL (Figure 7). We adminis-
tered sorafenib either by i.p. injection or oral gavage. In
both treatment methods, sorafenib plus TRAIL signifi-
cantly inhibited the continued growth of bax/ tumor xe-
nografts (i.p. injection: untreated versus treated bax/ tu-
mors, p = 0.0005; oral administration: untreated versus
treated bax/ tumors, p = 0.0558). We also examined
the combination of TRAIL plus sorafenib against bax+/cells, and observed enhancement of TRAIL-mediated ap-
optosis with sorafenib (Figure S5).
To confirm these results in another system, we used
TRAIL-resistant HT29 colon tumor cells. Mice bearing lu-
ciferase-expressing HT29 tumors were treated with sora-
fenib, TRAIL, or both. Comparison of the bioluminescence
signal before and after treatments showed a nearly 10-fold
decrease (p = 0.0002) in tumors from sorafenib + TRAIL
treated mice (Figure 8D). Evidence for apoptosis was
demonstrated by treatment-induced PARP cleavage
(Figure 8E) and nearly completes disappearance of tumor
cell mass accompanied by substantial fibrosis (Figure 8F).
Sorafenib alone showed no change in mean tumor size
(Figure 8C). PARP cleavage and fibrosis substitution of
tumor mass was observed, but to a lesser degree than
in tumors from the sorafenib + TRAIL treated group. Al-
though there was some PARP cleavage in the sorafenib
alone treatment group and this may have contributed toCancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc. 75
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Repressing TRAIL-Induced Mcl-1 and cIAP2Figure 8. TRAIL Combined with Sorafe-
nib Killed Tumor Cells in HT29 Xeno-
grafted Tumors
Cell lines indicated were treated with TRAIL or
sorafenib for 24 hr. (A) Plates of cells were
stained and fixed with Coomassie Blue, and
(B) lysates were collected and immunoblotting
performed. (C) Bioluminescence activity from
each tumor nodule was plotted in log scale.
Mean value of each group was marked as
a short horizontal solid line. Control group re-
ceived no treatment. (D) Relative ratio of biolu-
minescence signal was obtained by dividing
the bioluminescence signal after treatment by
the signal before treatment. Results are shown
as the mean (bar) ± SD. Significance of
difference was calculated by Student’s t test
analysis. (E) After bioluminescence imaging,
tumor tissues were harvested and subjected
to preparation of protein lysates and paraffin
embedding. Apoptosis in the tumor tissues
was detected bymeasuring cleavage of human
PARP. (F) H&E staining of tumor tissues.a delay in growth compared to control and TRAIL-treated
tumors, there was no obvious effect of sorafenib alone in
terms of tumor shrinkage. TRAIL treatment alone did not
affect tumor growth kinetics. Control- and TRAIL-treated
tumors showed tumor masses separated intermittently by
supporting connective tissues. Sorafenib-treated tumors
showed decreased size and an increase in fibrotic area.
There were very little tumor cell masses in sorafenib +
TRAIL treated tumors, andmassive fibrosis was observed.
These in vivo results using bax/ and p53 null HT29 tumor
xenografts suggest significant promise for combining76 Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc.sorafenib with TRAIL to treat cancers harboring defects
in apoptotic signaling.
DISCUSSION
Most cancer cells have defects in their ability to die by ap-
optosis. Activation of death receptor signaling, particularly
through TRAIL receptors, provides an exciting approach
for cancer therapy because of its potency, lack of signifi-
cant toxicity, and ability to kill cells with defective intrinsic
pathway apoptotic signaling. In some cells, referred to as
Cancer Cell
Repressing TRAIL-Induced Mcl-1 and cIAP2Type I, TRAIL signaling does not require the mitochondria
to kill (Ozoren and El-Deiry, 2002). Type I cells initiate suf-
ficient executioner caspase activity through the activity of
caspase 8/10 (Scaffidi et al., 1998). Type II cells require
activation of the intrinsic pathway following death receptor
activation through a process mediated by caspase cleav-
age of Bid.
Identifying cancer cell requirements for TRAIL sensitiv-
ity assumes greater significance now that TRAIL therapy
is in clinical trials. This may be crucial for the success of
TRAIL as a cancer therapy becausemany cancer cell lines
are not sensitive to TRAIL. A potential biomarker for iden-
tification of TRAIL sensitivity is oncogenic expression of
Myc (Ricci et al., 2004; Wang et al., 2004). However,
a high level of c-Myc expression is not the only require-
ment for TRAIL sensitivity. Cancer cells still need a func-
tional apoptotic signaling pathway for TRAIL to activate
a death response. While identifying patients with func-
tional TRAIL signaling pathways prior to treatment re-
mains as a goal in clinical trial design, one approach to
optimize TRAIL therapy is the pharmacological enhance-
ment of a cancer’s sensitivity to TRAIL. One way to over-
come TRAIL resistance is to convert Type II cells to Type I
cells, thereby bypassing the need for intact intrinsic path-
way. For example, DNA-damaging chemotherapy can
bypass HCT116 bax/ cell deficiency in mitochondrial
signaling by increasing p53 levels, leading to the in-
creased expression of DR5 and increased extrinsic path-
way signaling (LeBlanc et al., 2002; Wang et al., 2004).
An exciting finding presented here is that the combina-
tion of sorafenib and TRAIL is effective not only in tumor
cells with wild-type p53, but those that are p53-deficient
(e.g., HT29). This finding has important clinical implica-
tions for tumors with mutant p53 that are TRAIL-resistant.
Our initial examination of whether Myc can bypass Bax
deficiency to convert Type II tumor cells to a Type I pheno-
type led us to identify sorafenib’s ability to disable antia-
poptotic mechanisms activated by TRAIL in cells harbor-
ing defects in intrinsic apoptotic signaling. c-Myc can
sensitize bax/ cells to TRAIL, but in order to die by
apoptosis, these cells still require the intrinsic apoptotic
pathway. Therefore, even though c-FLIP expression is re-
pressed by c-Myc (Ricci et al., 2004), this suppression is
not sufficient to sustain activation of effector caspases
downstream of caspase 8 in the bax/ cells.
Our examination of c-Myc action on proteins involved
in maintaining mitochondrial membrane stability and
preventing caspase-mediated proteolysis led us to iden-
tify that TRAIL induced Mcl-1 and cIAP2 expression in
TRAIL resistant cells (Figure 2). The ability of TRAIL to
induce Mcl-1 and cIAP2 appears dependent on sup-
pression of the mitochondrial pathway of apoptosis
and appears to be independent of whether His-tagged
or native TRAIL is used (Figure S8). Blocking-activated
caspase 9 in HCT116 bax+/ cells with a pharmacologic
inhibitor, the stable expression of Bcl-xL, or through the
complete loss of Bax, resulted in TRAIL induction of
Mcl-1 and cIAP2 (Figure 3). c-Myc repressed TRAIL-
mediated induction of Mcl-1 and cIAP2 mRNA and pro-tein, indicating their potential importance in suppressing
TRAIL sensitivity.
We also examined mediators of TRAIL signaling previ-
ously identified to be targets of c-Myc, either directly or
through p53 stabilization. We did not observe significant
alterations in the expression of Bcl-2, Bcl-xL, or Bid, but
observed repressionof TRAIL-inducedBimwith c-Mycex-
pression, an observation that should not contribute toMyc
sensitization to TRAIL given theproapoptotic nature ofBim
(Figure 2). Pumawasnot further examinedbecause neither
exogenously expressed Myc nor TRAIL treatment alone
resulted in dramatic changes in its expression. The loss
of Bak following TRAIL treatment is intriguing, and its rele-
vance is under further investigation. c-Myc stabilized p53,
but knockdown studies in bax/ cells (Figure S1) and our
previous observations indicate that c-Myc does not re-
quire p53 to sensitize cells to TRAIL (Ricci et al., 2004).
Examination of the relative importance of Mcl-1 and
cIAP2 in mediating resistance to TRAIL signaling showed
that Mcl-1 can exert significant protection against TRAIL,
but cIAP2 appears less important (Figure 6). cIAP2 can in-
hibit caspases 3, 7, and 9 activity (Roy et al., 1997), but
can be inhibited by Smac/DIABLO andOmi/Htr2A (Creagh
et al., 2004; Yang et al., 2003; Yang and Du, 2004). There-
fore, it is possible that cIAP2 alone is not sufficient to block
TRAIL signaling when the mitochondrial membrane is de-
stabilized.
Our investigations into how TRAIL increased Mcl-1 and
cIAP2 expression led us to identify that both NF-kB and
Raf signaling play major roles. TRAIL activates both
NF-kB and Raf/MEK/ERK signaling in bax/ cells. ciap2
is a well-characterized NF-kB target gene (Wang et al.,
1998), and both ciap2 and mcl-1 were shown to be
CREB targets (Nishihara et al., 2004; Wang et al., 1999).
We found that TRAIL activation of NF-kB results in its
transcriptional activation of both ciap2 and mcl-1.
We testedwhether TRAIL could activate ciap2 andmcl-1
transcription through Raf/MEK/ERK signaling by using
the multikinase inhibitor, sorafenib. Sorafenib as a single
agent had little effect on the killing of bax/, HT29,
Calu6, or RKO cells, but combining it with TRAIL resulted
in high levels of cell death (Figures 4 and 8). As with
c-Myc, we found that sorafenib effectively prevents
TRAIL-mediated induction of Mcl-1 and cIAP2. Reintro-
duction of Mcl-1 or cIAP2 by transient transfection
confirmed that Mcl-1 plays an important role in sorafenib
control of TRAIL-resistance (Figure 6).
How do both sorafenib and Myc diminish TRAIL-in-
duced Mcl-1 and cIAP2? Decreased Mcl-1 and cIAP2
mRNA steady-state levels suggest that both sorafenib
and Myc affect transcriptional activation of these genes.
One potential mechanism is both diminish NF-kB signal-
ing. There are multiple reports showing Myc suppression
of NF-kB function (Keller et al., 2005; Klefstrom et al.,
1997; Sitcheran et al., 2005; Tanaka et al., 2002; You
et al., 2002).We tested directly whether sorafenib can alter
NF-kB transcription and found it reduced the amount of
TRAIL-induced RelA/p65 bound to these genes pro-
moters (Figure 5H). While we did not observe sorafenibCancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc. 77
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ment, there is substantial evidence that the DNA binding
and transactivation abilities of NF-kB are regulated by
multiple phosphorylation modifying events of the NF-kB
subunits (Viatour et al., 2005). Numerous kinases have
been identified that can phosphorylate NF-kB subunits.
These modifications also affect the ability of NF-kB to re-
cruit chromatin remodeling enzymes. Therefore, it is quite
probable that sorafenib acts to diminish NF-kB DNA bind-
ing to themcl-1 and ciap2 promoters by disrupting kinase
signaling important to the modification and enhanced
transactivation function of NF-kB subunits.
Two recent reports showed sorafenib treatment can re-
sult in downregulation of Mcl-1 levels in a variety of human
tumor cell lines (Rahmani et al., 2005; Yu et al., 2005). Nei-
ther study found that sorafenib affects steady-state Mcl-1
mRNA levels, but rather altered Mcl-1 expression at the
translational or posttranslational levels. No previous study
has examined the effects of sorafenib on cIAP2 or Mcl-1
levels in TRAIL-treated cells. Taken together, sorafenib ki-
nase inhibitionmay affect not only TRAIL-mediated NF-kB
activation of Mcl-1 transcription (Figure 5G), but it may
also diminish Mcl-1 through posttranscriptional mecha-
nisms. Furthermore, the combination of sorafenib plus
TRAIL also reduces p-CREB levels and this also may con-
tribute to the regulation of Mcl-1 expression.
Increased expression of Mcl-1 can mediate significant
protection against activation of the mitochondrial death
pathway. In the absence of Bax, the antiapoptotic proper-
ties of Mcl-1 take on greater significance because of the
highaffinity bindingbetweenMcl-1 andBakand the impor-
tanceof this interaction in apoptosis (Cuconati et al., 2003).
Our observations that c-Myc or sorafenib can prevent
TRAIL-mediated inductionofMcl-1 andcIAP2 levels, com-
bined with our overexpression and knockdown studies,
show that TRAIL protects cells from its own death signal
when caspase signaling is blocked. These results also
openupnewareasof investigation includingkinase targets
of sorafenib that ultimately impact on p65 binding to DNA
as well as which activities of this multikinase inhibitor are
ultimately responsible for its potent antitumor effect
when combined with TRAIL. These results also establish
the clinical potential for combiningTRAILwith an orally bio-
available, low-toxicity kinase inhibitor, sorafenib/Nexavar,
thus providing an exciting approach for attacking cancer
cells that harbor defective intrinsic apoptotic machinery.
EXPERIMENTAL PROCEDURES
Cell Death Assays
Sub-G1 DNA Content
Cells collected, fixed, and stained with propidium iodide were ana-
lyzed by flow cytometry using a Coulter-Beckman Elite Epics sorter.
Mitochondrial Membrane Potential
Cells were collected and incubated with 20 nM rhodamine 123, 3,30-di-
hexiloxadicarbocyanine [DiOC6] (Molecular Probes, Eugene OR) for
30 min then analyzed by flow cytometry. Percentage of cells with sub-
normal concentrations of DIOC6 have decreased mitochondrial mem-
brane potential are shown.78 Cancer Cell 12, 66–80, July 2007 ª2007 Elsevier Inc.Annexin V Staining
Cells were collected and incubated with red-shifted phycoerythrin-
conjugated recombinant human annexin V (CalTag, Burlingame, CA)
and analyzed by flow cytometry.
RNA Analysis
Five micrograms of total RNA were used in northern blot analysis per-
formed as previously described (Ricci et al., 2004). Radiolabeled DNA
probes using PCR-amplified products Mcl-1 and cIAP2 cDNAs were
used for hybridizations. Reverse transcription was done using Super-
script III reverse transcriptase (Invitrogen) and oligo-dT primers with
1 mg of total RNA at 50C for 1 hr in a 20 ml reaction. Real-time PCR
was performed using using ABI TaqMan Universal PCR Master Mix
PCR and the Applied Biosystems 7700 sequence detector. Primer
sequences are provided in the Supplemental Data.
siRNA-Mediated Knockdown
Double-stranded RNA oligonucleotides directed toward cIAP2, Mcl-1,
and a negative control (Allstars Negative siRNA) were purchase from
Qiagen. Transfections were carried out using Lipofectamine 2000
according to manufacturer’s instructions (Invitrogen).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation experiments were performed essen-
tially as described (Ricci et al., 2004)but with the following changes:
NF-kB ChIP was done with one round of immunoprecipiation using
a RelA/p65 antibody (H-286, Santa Cruz). Primers used are provided
in Supplementary Data.
Tumor Xenograft Experiments
Female athymic NCr-nu/nu mice (Taconic Farms, Germantown, NY)
were used for all studies. The mice were housed and maintained in ac-
cordance with the University of Pennsylvania Institutional Animal Care
and Use Committee and state and federal guidelines for the humane
treatment and care of laboratory animals.
bax/ Xenografts
Two million bax/ cells were injected s.c. into the right and left flanks
of each mouse and allowed to grow for three days. Noninvasive biolu-
minescence (photons/sec/cm2/steradian) signals were visualized by
intraperitoneal injection of 5mg D-luciferin into anesthetizedmice (ket-
amine/xylazine), followed by detection of live images using a Xenogen
IVIS System as described (Wang and El-Deiry, 2003). A Cremophor EL/
ethanol/water solution (12.5% Cremophor EL/ 12.5% ethanol/ 75%
water) containing sorafenib was prepared as previously described
(Wilhelm et al., 2004) and 60 mg/kg was administered by intraperito-
neal injection or by oral gavage. TRAIL was prepared in PBS and
100 mg/mouse was administered by intravenous tail vein injection.
HT29 Xenografts
HT29 Cells were suspended in 50% Matrigel and injected subcutane-
ously into two sites per mouse. Three million cells were used per injec-
tion. Mice were subjected to imaging within 15–30 min after intraperi-
toneal injection of D-luciferein under anesthesia. Treatment was given
daily with 30mg/kg of sorafenib and/or 5mg/kg of his-TRAIL for 4 con-
secutive days. Treatmentwas started 11 days after injection. Sorafenib
was given IP and TRAIL by IV. Control and TRAIL treated group consist
of 4 mice/8 tumors; and sorafenib and sorafenib plus TRAIL groups
had 5 mice/10 tumors. Bioluminescence imaging was taken before
the first treatment and 24 hr after final treatment.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and eight supplemental figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/12/1/66/DC1/.
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